Manage uncontrolled and resistant hypertension and decide when to look for secondary hypertension, per the 2026 ISH Global Hypertension Practice Guidelines — excluding pseudo-resistance, the resistant-hypertension drug sequence (spironolactone as 4th drug), new drug classes (aldosterone synthase inhibitors, aprocitentan, non-steroidal MRA, zilebesiran), renal denervation criteria, the common secondary causes (primary aldosteronism, renal parenchymal disease, OSA, renal artery stenosis), red flags that should trigger a secondary workup, and BP-raising drugs. Use when a clinician asks "BP not controlled on three drugs", "is this resistant hypertension", "what to add as fourth drug", "spironolactone in resistant hypertension", "when to screen for secondary hypertension", "young patient with high BP", "hypokalaemia and hypertension", "should I check aldosterone renin ratio", "renal denervation indications", or "baxdrostat aprocitentan". Source: Stergiou GS et al, 2026 ISH Global Hypertension Practice Guidelines, J Hypertens 2026 (DOI 10.1097/HJH.0000000000004451).